Methadone - Revision history

Lazy at 08:16, 18 January 2025

2025-01-18T08:16:32Z

← Older revision		Revision as of 01:16, 18 January 2025
Line 15:		Line 15:
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.		\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		\|overview=Methadone, FDA-approved for pain management and addiction therapy, is currently being investigated for its potential chemosensitizing effects in glioblastoma treatment, showing promising preliminary results in progression-free survival when combined with standard care. While generally exhibiting low toxicity and manageable side effects such as nausea and constipation, further research is necessary to confirm its efficacy and optimal dosing in this context.}}

69.163.248.232 at 18:58, 12 November 2024

2024-11-12T18:58:23Z

← Older revision		Revision as of 11:58, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.		\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
	\|~~treatment_treatment_treatment_category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.		\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:23:07Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:23, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.		\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
	\|~~treatment_treatment_category~~=Repurposed Drugs		\|treatment_treatment_treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.		\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:16:13Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:16, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.		\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
	\|~~treatment_category~~=Repurposed Drugs		\|treatment_treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.		\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:15:11Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:15, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.		\|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.		\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		}}

Lazy at 16:52, 27 March 2024

2024-03-27T16:52:15Z

← Older revision		Revision as of 09:52, 27 March 2024
Line 13:		Line 13:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=The toxicity level for Methadone, when used for investigational purposes in treating glioblastoma, is relatively low. It is well-established for its use in pain management and replacement therapy for addiction, known to have common side effects such as nausea and constipation, which usually resolve after one month. It has been found to have potential as a chemosensitizer in glioma cells, meaning that it makes the cancer cells more sensitive to chemotherapy. However, this use is currently in the research and investigative stage. It's important to note that the side effects may vary among individuals, and adequate supervision from healthcare providers is necessary during administration of this treatment.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Methadone (D,L-methadone) |FDA_approval=Yes (for pain management and replacement therapy for addiction) |used_for=Investigational use in glioblastoma treatment for its chemosensitizing effects |clinical_trial_phase=Preclinical studies and a retrospective safety and tolerability study in glioma patients |common_side_effects=Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy |OS_without=Not specified in..."

2024-03-19T16:41:18Z

Created page with "{{TreatmentInfo |drug_name=Methadone (D,L-methadone) |FDA_approval=Yes (for pain management and replacement therapy for addiction) |used_for=Investigational use in glioblastoma treatment for its chemosensitizing effects |clinical_trial_phase=Preclinical studies and a retrospective safety and tolerability study in glioma patients |common_side_effects=Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy |OS_without=Not specified in..."

New page

{{TreatmentInfo
|drug_name=Methadone (D,L-methadone)
|FDA_approval=Yes (for pain management and replacement therapy for addiction)
|used_for=Investigational use in glioblastoma treatment for its chemosensitizing effects
|clinical_trial_phase=Preclinical studies and a retrospective safety and tolerability study in glioma patients
|common_side_effects=Nausea, constipation (obstipation); side effects commonly resolved after one month of therapy
|OS_without=Not specified in provided details
|OS_with=In a study with newly diagnosed GBM patients, progression-free survival at 6 months was 91% when methadone was added to the standard of care
|PFS_without=Not specified
|PFS_with=Significant in the context of preliminary findings from retrospective studies
|usefulness_rating=3
|notes=Methadone, primarily known for severe pain management and opioid replacement therapy, has demonstrated potential as a chemosensitizer in glioma cells through in vitro studies and mouse models. It exhibits this effect by inhibiting the activity of the DNA-repair enzyme MGMT and sensitizing cells to chemotherapy, along with blocking adenyl cyclase leading to decreased expression of anti-apoptotic proteins. Early clinical data suggest a positive impact on progression-free survival in glioblastoma patients when combined with standard treatments, although further research is needed to confirm efficacy and optimal dosing.
|category=Repurposed Drugs
|links=
}}